Covid19COVID19@SpainNCT04355871
Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain
An observational study of Covid19, run by Fundacion SEIMC-GESIDA at 128 sites in Spain.
Trial summary
COVID-19@Spain is a retrospective cohort study that aims to determine the clinical characteristics of hospitalized patients with COVID-19 in Spain and to identify prognostic factors of mortality and the need for mechanical ventilation Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Covid19
- How many people
- 4,035 participants
- Where
- 128 sitesSpain
- Study dates
- 18 Mar 2020to 17 Apr 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Investigators from participating centers were asked to include the first consecutive hospitalized patients (up to 100) meeting the study criteria from the start of the epidemic until March 17, 2020.
Who may be able to join
- Laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay
- Hospital admission
Who cannot join
- None
Trial locations and contacts
128 sites in 1 country.
128 sites in 1 country
Spain128 sites
Comp. Hosp. Univ. A Coruña
A Coruña
H. Quiron A Coruña
A Coruña
H. de Alcaniz
Alcañiz
H. Gral Univ. de Alicante
Alicante
H. Univ. San Juan de Alicante
Alicante
H. Univ. de la Ribera
Alzira
H. Santos Reyes
Aranda de Duero
Hospital Alto Deba
Arrasate / Mondragón
H. Dr. Jose Molina Orosa
Arrecife
Complejo Asistencial de Avila
Ávila
Consorcio Sanitari Integral (CAIDM)
Barcelona
H. Clinic
Barcelona
H. del Mar
Barcelona
H. Parc Sanitari Sant Joan de Deu
Barcelona
H. Santa Creu y Sant Pau
Barcelona
H. Univ. de Bellvitge
Barcelona
H. Vall d'Hebron
Barcelona
Hospital CIMA-Sanitas
Barcelona
SCIAS H. de Barcelona
Barcelona
H. Clinica de Benidorm
Benidorm
H. de Cruces
Bilbao
H. San Eloy_Barakaldo
Bilbao
H. Univ. de Basurto
Bilbao
H. Urduliz-Alfredo Espinosa
Bilbao
H. Gral de La Palma
Breña Alta
H. de Puerto Real
Cadiz
H. de Calahorra
Calahorra
H. Sant Jaume de Calella
Calella
H. Univ Santa Lucia
Cartagena
H. Univ de Henares
Coslada
Hospital Marina Salud de Dénia
Denia
Hospital Don Benito-Villanueva de la Serena
Don Benito
H. Gral Univ. de Elche
Elche
H. Univ. del Vinalopo
Elche
Comp. Hospt. Univ. de Ferrol
Ferrol
H. Francesc de Borja
Gandia
H. Comarcal de Blanes
Girona
H. de Figueres
Girona
H. Josep Trueta
Girona
H. Clinico San Cecilio
Granada
Hospital HLA Inmaculada
Granada
H. de Guadalajara
Guadalajara
H. de Guadarrama
Guadarrama
H. Juan Ramón Jiménez
Huelva
H. Riotinto
Huelva
H. Can Misses
Ibiza Town
H. Universitario de Jaén
Jaén
H. Univ. de Jerez de la Frontera
Jerez de la Frontera
H. Univ Insular de Gran Canaria
Las Palmas de Gran Canaria
H. Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria
H. Univ. Severo Ochoa
Leganés
H. San Pedro
Logroño
H. Univ. Menez Rafael Mendez
Lorca
H. Lucus Augusti
Lugo
H. 12 de Octubre
Madrid
H. Clinica Univ. de Navarra_ Campus Madrid
Madrid
H. Clinico San Carlos
Madrid
H. Fundacion Jiménez Díaz
Madrid
H. Gral de la Defensa Gomez Ulla
Madrid
H. HLA Univ. Moncloa
Madrid
H. HM Sanchinarro
Madrid
H. Puerta de Hierro
Madrid
H. Univ HM Madrid
Madrid
H. Univ Principe de Asturias
Madrid
H. Univ. de Alcorcón
Madrid
H. Univ. de Getafe
Madrid
H. Univ. de Móstoles
Madrid
H. Univ. Gregorio Marañon
Madrid
H. Univ. HM Monteprincipe
Madrid
H. UNiv. HM Puerta del Sur
Madrid
H. Univ. Infanta Leonor
Madrid
H. Univ. La Paz
Madrid
H. Univ. La Princesa
Madrid
H. Univ. Ramón y Cajal
Madrid
H. Univ. Rey Juan Carlos
Madrid
H. Marbella Internacional
Málaga
H. Virgen de la Victoria
Málaga
H. Costa del Sol
Marbella
H. de Mataro
Mataró
H. de Melilla
Melilla
H. de Mendaro
Mendaro
H. Virgen de la Arrixaca
Murcia
H. Vega Baja
Orihuela
H. Univ. Central de Asturias
Oviedo
H. de Palamos
Palamós
H. Son Espases
Palma de Mallorca
H. Son Llatzer
Palma de Mallorca
H. Clinica Univ. Navarra
Pamplona
H. Virgen del Puerto
Plasencia
H. El Bierzo
Ponferrada
H. Do Salnes
Pontevedra
H. UNiv. Los Arcos del Mar Menor
Pozo-Aledo
H. Santa Barbara
Puertollano
H. Parc Tauli
Sabadell
Complejo Asist. Univ. de Salamanca
Salamanca
H. de Donostia
San Sebastián
H. Infanta Sofia
San Sebastián de los Reyes
H. de l'Esperit Sant
Santa Coloma de Gramenet
H. U. de Canarias
Santa Cruz de Tenerife
H. Univ. Nuestra Sra. de la Candelaria
Santa Cruz de Tenerife
H. Univ. Marques de Valdecilla
Santander
H. Clinico Univ. Santiago de Compostela
Santiago de Compostela
H. Univ de Valme
Seville
H. Univ. Virgen del Rocio
Seville
H. Univ. Virgen Macarena
Seville
H. Virgen Macarena
Seville
H. Univ Joan XXIII
Tarragona
H. Mutua de Terrasa
Terrassa
Complejo Hospitalario Virgen de la Salud
Toledo
H. Univ. HM Torrelodones
Torrelodones
H. Quiron Salud Torrevieja
Torrevieja
H. Virgen de la Cinta
Tortosa
H. Reina Sofia de Tudela
Tudela
H. Arnau de Vilanova-Lliria
Valencia
H. Clinico Univ. de Valencia
Valencia
H. de Sagunto
Valencia
H. Univ. y Polit. La Fe
Valencia
H. Clin. Univ. de Valladolid
Valladolid
H. Rio Hortega
Valladolid
H. Alvaro Cunqueiro
Vigo
H. de Viladecans
Viladecans
H. de la Marina Baixa
Villajoyosa
Hospital de la Plana
Villarreal de Huerva
H. Univ de Alava
Vitoria-Gasteiz
H. Virgen de la Concha
Zamora
H. Lozano Blesa
Zaragoza
H. Miguel Servet
Zaragoza
H. Ntra. Sra. de Gracia
Zaragoza
About this study
Official title: Characteristics and Predictors of Death Among Hospitalized Patients With COVID-19 in Spain
COVID-19@Spain is a retrospective cohort study that aims to determine the clinical characteristics of hospitalized patients with COVID-19 in Spain and to identify prognostic factors of mortality and the need for mechanical ventilation
Read the detailed description
COVID-19@Spain is a retrospective cohort study of patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The Ethics Committee for Research with Medicines of Hospital General Universitario Gregorio Marañón approved the study and waived informed consent for the collection of clinical data.
Investigators from participating centers were asked to include the first consecutive hospitalized patients (up to 100) meeting the study criteria from the start of the epidemic until March 17, 2020.
The data source was the electronic medical records. All data were entered directly by personnel at each institution using an online case report form (CRF), that satisfied local requirements of data confidentiality.
The variables registered included administrative data, epidemiological information, type of clinical specimen in which the diagnosis was confirmed, and the RT-PCR cycle threshold (Ct) of the confirmatory gene. We also registered demographics, comorbidities and current medications, signs and symptoms at admission, baseline laboratory tests results, chest X-ray findings at baseline and during follow-up, complications during hospitalization, medications with potential activity against COVID-19, and supportive treatments including oxygen therapy, admission to intensive care unit (ICU), mechanical ventilation (intubation), and use of adjuvant anti-inflammatory medications such as tocilizumab and systemic corticosteroids. Drug-related adverse events of medications for COVID-19 needing discontinuation were also recorded. The clinical status of the patients as of April 17, 2020, was categorized as discharged alive (with the date of discharge), alive and currently hospitalized, and death (with the date of death).
The primary endpoint is all-cause mortality at day 28, and the secondary endpoint is the need for mechanical ventilation. Baseline was the date of hospital admission. The follow-up censoring date is April 17, 2020.
- Conditions
- Covid19
- Keywords
- Covid19, SARS-CoV-2, Coronavirus
- Medical subject headings
- COVID-19, Coronavirus Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall mortality
Measured: 28 days
Secondary outcomes (1)
Mechanical ventilation
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Apr 2020
- Study start18 Mar 2020
- Primary completion15 Apr 2020
- Study completion17 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 4,035 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundacion SEIMC-GESIDA
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jose Ramón Arribas, MD, Principal investigator, H. Univ. La PazJuan Berenguer, MD, Principal investigator, H. Univ. Gregorio MarañónPablo Ryan, MD, Principal investigator, H. Univ. Infanta LeonorJesús Rodriguez Baños, MD, Principal investigator, H. Univ. Virgen MacarenaJordi Carratala, MD, Principal investigator, H. Univ. de BellvitgeJerónimo Pachón, MD, Principal investigator, H. Univ. VIrgen del Rocio
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04355871
- Sponsor's protocol ID
- COVID-19/SEIMC-FSG
- Acronym
- COVID19@Spain
- Status last verified
- Apr 2020
- First submitted
- 19 Apr 2020
- Last updated
- 3 Jul 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characteristics and Predictors of Death Among Hospitalized Patients With COVID-19 in Spain
- ClinicalTrials.gov ID
- NCT04355871
- Acronym / sponsor ID
- COVID19@Spain / COVID-19/SEIMC-FSG
- Conditions
- Covid19
- Keywords
- Covid19, SARS-CoV-2, Coronavirus
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 4,035 participants (actual)
- Lead sponsor
- Fundacion SEIMC-GESIDAUniversity, hospital or other
- Study start
- 18 Mar 2020 (actual)
- Primary completion
- 15 Apr 2020 (actual)
- Study completion
- 17 Apr 2020 (actual)
- First posted
- 21 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
COVID-19@Spain is a retrospective cohort study that aims to determine the clinical characteristics of hospitalized patients with COVID-19 in Spain and to identify prognostic factors of mortality and the need for mechanical ventilation
Detailed description
COVID-19@Spain is a retrospective cohort study of patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The Ethics Committee for Research with Medicines of Hospital General Universitario Gregorio Marañón approved the study and waived informed consent for the collection of clinical data.
Investigators from participating centers were asked to include the first consecutive hospitalized patients (up to 100) meeting the study criteria from the start of the epidemic until March 17, 2020.
The data source was the electronic medical records. All data were entered directly by personnel at each institution using an online case report form (CRF), that satisfied local requirements of data confidentiality.
The variables registered included administrative data, epidemiological information, type of clinical specimen in which the diagnosis was confirmed, and the RT-PCR cycle threshold (Ct) of the confirmatory gene. We also registered demographics, comorbidities and current medications, signs and symptoms at admission, baseline laboratory tests results, chest X-ray findings at baseline and during follow-up, complications during hospitalization, medications with potential activity against COVID-19, and supportive treatments including oxygen therapy, admission to intensive care unit (ICU), mechanical ventilation (intubation), and use of adjuvant anti-inflammatory medications such as tocilizumab and systemic corticosteroids. Drug-related adverse events of medications for COVID-19 needing discontinuation were also recorded. The clinical status of the patients as of April 17, 2020, was categorized as discharged alive (with the date of discharge), alive and currently hospitalized, and death (with the date of death).
The primary endpoint is all-cause mortality at day 28, and the secondary endpoint is the need for mechanical ventilation. Baseline was the date of hospital admission. The follow-up censoring date is April 17, 2020.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Investigators from participating centers were asked to include the first consecutive hospitalized patients (up to 100) meeting the study criteria from the start of the epidemic until March 17, 2020.
Key inclusion criteria (2 listed)
- Laboratory-confirmed COVID-19 infection by real-time polymerase chain reaction (RT-PCR) assay
- Hospital admission
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall mortality
Time frame: 28 days
1 secondary outcome
Mechanical ventilation
Time frame: 28 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jose Ramón Arribas, MD principal investigator
H. Univ. La Paz
Juan Berenguer, MD principal investigator
H. Univ. Gregorio Marañón
Pablo Ryan, MD principal investigator
H. Univ. Infanta Leonor
128 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by Fundacion SEIMC-GESIDA at 128 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 128 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall mortality (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2023.